Opioid Kappa Receptor Selective Agonist TRK-820 (Nalfurafine Hydrochloride)

Hideaki Fujii, Shigeto Hirayama and Hiroshi Nagase

School of Pharmacy, Kitasato University

Japan

1. Introduction

TRK-820 (nalfurafine hydrochloride) is a selective opioid κ receptor agonist (Fig. 1) that was launched as an antipruritic for hemodialysis patients in Japan in 2009. In general, clinically used opioids, such as morphine, exhibit potent antinociceptive effects and simultaneous severe adverse effects, including drug dependence, derived from the opioid μ receptor. To develop analgesics without drug dependence, κ receptor agonists are investigated. However, conventional κ agonists, arylacetamide derivatives, showed aversive effects like psychotomimetic effects, and have not yet been used clinically. On the other hand, the novel κ agonist TRK-820 has no dependent or aversive properties. TRK-820, which has a structure different from arylacetamides, was first developed as an analgesic for postoperative pain, but the indication was changed to pruritus (Nakao & Mochizuki, 2009; Nagase & Fujii, 2011). The rational drug design and synthesis of the compound have been reported (Kawai et al., 2008; Nagase et al., 1998; Nagase & Fujii, 2011); therefore, in this chapter, we will focus on its pharmacological properties.

Fig. 1. Structure of nalfurafine hydrochloride (TRK-820)

2. Opioid receptor type selectivity (In vitro)

The binding affinities of TRK-820 were evaluated using various tritiated ligands and opioid receptors derived from various species (Table 1). The κ selectivity over the δ receptor (Ki ratio δ/κ) tended to be higher than over the μ receptor (Ki ratio μ/κ). Binding affinities for the L-type Ca^{2+} channel and 45 receptors, except the opioid receptors, were examined (Nakao & Mochizuki, 2009). Among the tested receptors, TRK-820 showed the strongest affinity for the muscarine M1 receptor, but its Ki value was 1,700 nmol/L and approximately 7,000 times higher than that of the κ receptor. A comparison of the binding properties of TRK-820 and a conventional κ agonist, U-69,593, was noteworthy. In a competitive binding
Table 1. Binding affinities ($K_i$ values) and selectivities ($K_i$ ratios) of TRK-820 for the opioid receptors. Seki et al. used $[^{3}H]$bremazocine and the recombinant rat opioid receptors. Wang, Y et al. used $[^{3}H]$diprenorphine and recombinant rat $\mu$, recombinant mouse $\delta$, and recombinant human $\kappa$ receptors. Vanderah et al. used $[^{3}H]$DAMDO, $[^{3}H]$pCl-DPDPE, and $[^{3}H]$U-69,593 for the recombinant human $\mu$, $\delta$, and $\kappa$ receptors, respectively. Nakao et al. used $[^{3}H]$diprenorphine and the recombinant human receptors. Nagase et al. used $[^{3}H]$DAMDO, $[^{3}H]$NTI, and $[^{3}H]$U-69,593 for the $\mu$, $\delta$, and $\kappa$ receptors, respectively. Guinea pig forebrain or guinea pig cerebellum was used to assay the $\mu$ and $\delta$ receptor or $\kappa$ receptor, respectively.

<table>
<thead>
<tr>
<th>$K_i$ (nM)</th>
<th>$K_i$ ratio</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>$\mu$</td>
<td>$\delta$</td>
<td>$\kappa$</td>
</tr>
<tr>
<td>53</td>
<td>1200</td>
<td>3.5</td>
</tr>
<tr>
<td>5.2</td>
<td>161</td>
<td>0.075</td>
</tr>
<tr>
<td>0.71</td>
<td>49.9</td>
<td>0.36</td>
</tr>
<tr>
<td>2.21</td>
<td>484</td>
<td>0.244</td>
</tr>
<tr>
<td>0.582</td>
<td>96.5</td>
<td>0.225</td>
</tr>
</tbody>
</table>

Table 2. Selectivities of TRK-820 in various functional assays. Selectivity in MVD and GPI assays was obtained by $K_e$ ratios. The selectivity for the $\kappa$ receptor over the $\delta$ receptor in the MVD assay was not calculated (NC) due to a lack of agonist activity for the $\delta$ receptor. The selectivity for the $\kappa$ receptor over the $\delta$ receptor in the GPI assay was not obtained because GPI preparation contained only the $\mu$ and $\kappa$ receptors. Seki et al. and Nakao et al. used the recombinant rat and human receptors in their assays, respectively. In the $[^{35}S]$GTP$\gamma$S binding assay, recombinant rat $\mu$, recombinant mouse $\delta$, or recombinant human $\kappa$ receptors were used.

<table>
<thead>
<tr>
<th>Assay</th>
<th>Selectivity</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$\mu/\kappa$</td>
<td>$\delta/\kappa$</td>
</tr>
<tr>
<td>MVD</td>
<td>980</td>
<td>NC</td>
</tr>
<tr>
<td>GPI</td>
<td>78.6</td>
<td>-</td>
</tr>
<tr>
<td>cAMP (Sato et al.)</td>
<td>55</td>
<td>$&gt;6,667$</td>
</tr>
<tr>
<td>cAMP (Nakao et al.)</td>
<td>203</td>
<td>2,610</td>
</tr>
<tr>
<td>$[^{35}S]$GTP$\gamma$S</td>
<td>128</td>
<td>11,560</td>
</tr>
</tbody>
</table>

assay using $[^{3}H]$TRK-820, TRK-820 completely replaced $[^{3}H]$TRK-820 binding, whereas U-69,593 did not replace it completely, with roughly 20% of $[^{3}H]$TRK-820 binding remaining. Moreover, Scatchard analysis of $[^{3}H]$TRK-820 and $[^{3}H]$U-69,593 binding using guinea pig cerebellum showed that TRK-820 had stronger binding affinity than U-69,593 ($K_d$ values: 0.46±0.03 nM for $[^{3}H]$TRK-820, 1.17±0.14 nM for $[^{3}H]$U-69,593) and that the $B_{max}$ value for $[^{3}H]$TRK-820 (284±43.3 fmol/mg protein) was significantly higher than the value for $[^{3}H]$U-69,593 (83.7±7.86 fmol/mg protein). Even in the presence of $\mu$ agonist DAMDO (100 nM) and $\delta$ agonist DPDPE (200 nM), the $K_d$ and $B_{max}$ values for $[^{3}H]$TRK-820 did not change ($K_d$ = 0.51±0.03 nM, $B_{max}$ = 265±27.2 fmol/mg protein) (Endoh et al., 2000). These results suggest that TRK-820 was selective ligand for the $\kappa$ receptor and that its binding property for the $\kappa$ receptor was different from that of the conventional $\kappa$ agonist U-69,593. Many binding
assays are carried out using \(^{3}H\)U-69,593 because it is commercially available. However, the binding property of TRK-820 is difficult to be definitively evaluated because \(^{3}H\)TRK-820 is not available now.

TRK-820 was selective for the \(\kappa\) receptor, but the selectivity over the \(\mu\) receptor was apparently not as high in the binding assays. Contrarily TRK-820 showed more selectivities for the \(\kappa\) receptor in functional assays: MVD (mouse vas deference) and GPI (guinea pig ileum) assay (Nagase et al., 1998), cAPM assay (Nakao & Mochizuki, 2009; Seki et al., 1999), and \([^{35}S]GTP\gammaS\) binding assay (Wang, Y et al., 2005) (Table 2). The results of the cAMP assay (IC\(_{50}\) (\(\mu\)) = 8.3±1.4 nM, I\(_{\text{max}}\) (\(\mu\)) = 69±3%, IC\(_{50}\) (\(\delta\)) > 1,000 nM, I\(_{\text{max}}\) (\(\delta\)) not determined, IC\(_{50}\) (\(\kappa\)) = 0.15±0.07 nM, I\(_{\text{max}}\) (\(\kappa\)) = 81±3% by Seki et al.; IC\(_{50}\) (\(\mu\)) = 1.66±0.09 nM, I\(_{\text{max}}\) (\(\mu\)) = 53.2±1.3%, IC\(_{50}\) (\(\delta\)) = 21.3±1.0 nM, I\(_{\text{max}}\) (\(\delta\)) = 77.9±1.6%, IC\(_{50}\) (\(\kappa\)) = 0.00816±0.00138 nM, I\(_{\text{max}}\) (\(\kappa\)) = 91.3±0.5% by Nakao et al.) indicated that TRK-820 was a selective and potent full agonist for the \(\kappa\) receptor and partial agonist for the \(\mu\) and \(\delta\) receptors. The potency for the \(\delta\) receptor was very low (Nakao & Mochizuki, 2009; Seki et al., 1999). The \([^{35}S]GTP\gammaS\) binding assay provided similar results (EC\(_{50}\) (\(\mu\)) = 3.2±1.3 nM, E\(_{\text{max}}\) (\(\mu\)) = 54±7%, EC\(_{50}\) (\(\delta\)) = 289±60 nM, E\(_{\text{max}}\) (\(\delta\)) = 51±6%, EC\(_{50}\) (\(\kappa\)) = 0.025±0.003 nM, E\(_{\text{max}}\) (\(\kappa\)) = 93±5%) (Wang, Y et al., 2005). Mizoguchi et al. exhibited partial agonist activity of TRK-820 for the \(\mu\) receptor in both in vitro and in vivo assays (Mizoguchi et al., 2003). TRK-820 concentration- or dose-dependently attenuated \([^{35}S]GTP\gammaS\) binding by DAMGO or antinociception induced by intracerebroventricular (i.c.v.) administration of DAMGO. On the other hand, the effects of morphine alone or a mixture with TRK-820 were investigated using a mouse acetic acid-induced writhing test or warm water (50 °C) tail-withdrawal assay in rhesus monkeys (Ko & Husbands, 2009; Nagase, 2010). Isobologram analysis of the results showed that additive or synergetic effects for TRK-820 in combination with morphine in the antinociceptive effect were observed, indicating that TRK-820 had no \(\mu\) antagonist activity, at least no antagonism against analgesic activity induced by morphine. Why the effects of TRK-820 against DAMGO differed from those against morphine is not clear.

---

Fig. 2. Isobologram for the mixture of TRK-820- and morphine-induced antinociception in the mouse acetic acid-induced writhing test. Reprinted with permission from Nagase, 2010.
3. Analgesic effects

TRK-820 showed potent analgesic effects in some species (rodents and primates) with various stimuli: chemical, thermal, or mechanical stimuli and inflammatory, diabetic, herpetic, and postherpetic pain models. The antinociceptive effects of TRK-820 are summarized in Tables 3-7. Subcutaneous (s.c.) administration of TRK-820 produced dose-dependent and profound antinociceptive effects in the low temperature hot plate, tail flick, tail pressure, and tail pinch tests. However, TRK-820 was not as effective in high temperature hot plate tests (Table 3) (Endoh et al., 1999).

In a rat paw pressure test, TRK-820 given s.c. or intramuscularly (i.m.) induced dose-dependent and sufficient analgesic effects, which were suppressed by pre-treatment with selective κ antagonist nor-BNI (Table 3). The antinociceptive effect by TRK-820 (ED$_{50}$ = 0.064 mg/kg, s.c.) was 170, 2, 20, and 78-fold more potent than U-50,488H, CI-977, morphine, and pentazocine, respectively (ED$_{50}$ values : 11.0, 0.15, 1.3, and 5.0 mg/kg) (Endoh et al., 2000).

<table>
<thead>
<tr>
<th>Compound</th>
<th>High temperature hot plate (55 °C)</th>
<th>Low temperature hot plate (51 °C)</th>
<th>Tail flick</th>
<th>Tail pressure</th>
<th>Tail pinch</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRK-820</td>
<td>32.0 % at 0.2</td>
<td>0.129</td>
<td>0.062</td>
<td>0.009</td>
<td>0.035</td>
</tr>
<tr>
<td>U-50,488H</td>
<td>63.8 % at 20</td>
<td>8.71</td>
<td>5.18</td>
<td>1.0</td>
<td>11.5</td>
</tr>
<tr>
<td>ICI-199,441</td>
<td>n.t.</td>
<td>0.065</td>
<td>0.042</td>
<td>0.024</td>
<td>0.051</td>
</tr>
<tr>
<td>U-69,593</td>
<td>n.t.</td>
<td>1.33</td>
<td>n.t.</td>
<td>0.48</td>
<td>2.8</td>
</tr>
<tr>
<td>CI-977</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
</tr>
<tr>
<td>PD-117302</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
</tr>
<tr>
<td>Pentazocine</td>
<td>44.6 % at 40</td>
<td>52.2</td>
<td>n.t.</td>
<td>n.t.</td>
<td>n.t.</td>
</tr>
<tr>
<td>Morphine</td>
<td>3.65</td>
<td>5.30</td>
<td>5.26</td>
<td>1.5</td>
<td>12.2</td>
</tr>
</tbody>
</table>

Table 3. ED$_{50}$ values (mg/kg, s.c.) of the antinociceptive effects of some opioid agonists in various tests. U-50,488H, U-69,593, ICI-199,441, CI-977, and PD-117302 are conventional κ agonists. n.t. : not tested. Hot plate, tail flick, tail pressure, tail pinch, and acetic acid-induced writhing tests were performed in mice (Endoh et al., 1999). Paw pressure and formalin tests were performed in rats (Endoh et al., 2000).
In the formalin test, s.c. TRK-820 given 15 min prior to the formalin injection markedly inhibited the second phase of the nociceptive response induced by formalin in a dose-dependent manner. However, the analgesic effect of TRK-820 was low for the first phase of the formalin response. Similarly, a conventional κ agonist, ICI-199,441, also markedly inhibited the second phase. On the other hand, a μ agonist, morphine inhibited both phases in a dose-dependent manner. The antinociceptive potencies of TRK-820 and ICI-199,441 were almost equivalent (Table 3) (Endoh et al., 2000). A potent and dose-dependent antinociceptive effect of TRK-820 (i.m.) was also observed in cynomolgus monkeys. The analgesic effect of TRK-820 was 295 and 492-fold more potent than that of morphine in the 50 °C and 55 °C hot water tests, respectively, and 40 and 1000-fold more potent than that of U-50,488H and pentazocine in the 50 °C hot water test, respectively (Table 4) (Endoh et al., 2001).

Furthermore, the antinociceptive effects of TRK-820 administered s.c. and perorally (p.o.) were compared. The dose-dependent antinociception of TRK-820 (ED₅₀ = 0.0033 mg/kg, s.c. and 0.032 mg/kg, p.o.) in the acetic acid-induced writhing test were inhibited by pretreatment with nor-BNI. The antinociceptive effects induced by s.c. or p.o. administration of TRK-820 were 351 and 796-fold more potent than those induced by U-50,488H, respectively, and 175 and 187-fold more potent than those induced by morphine, respectively. Because the ED₅₀ p.o./s.c. ratio for TRK-820 was the least among the tested compounds, TRK-820 was expected to be the most effective agent when administered p.o. (Table 5) (Endoh et al., 1999). Intravenous administration of TRK-820 was also reported to be effective in the same test (Vanderh et al., 2008).

The effect of repeated administration of some κ agonists and morphine on antinociceptive tolerance was examined by the acetic acid-induced writhing test in mice. After five

<table>
<thead>
<tr>
<th>Compound</th>
<th>50 °C hot water</th>
<th>55 °C hot water</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRK-820</td>
<td>0.0078</td>
<td>0.012</td>
</tr>
<tr>
<td>Morphine</td>
<td>2.3</td>
<td>5.9</td>
</tr>
<tr>
<td>U-50,488H</td>
<td>0.31</td>
<td>n.t.</td>
</tr>
<tr>
<td>Pentazocine</td>
<td>&gt; 10</td>
<td>n.t.</td>
</tr>
</tbody>
</table>

Table 4. ED₅₀ values (mg/kg, i.m.) of antinociceptive effects induced by some opioid agonists in the hot water tail withdrawal test in cynomolgus monkeys. n.t.: not tested.

<table>
<thead>
<tr>
<th>Compound</th>
<th>s.c.</th>
<th>p.o.</th>
<th>ED₅₀ p.o./s.c. ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRK-820</td>
<td>0.0033</td>
<td>0.032</td>
<td>9.7</td>
</tr>
<tr>
<td>U-50,488H</td>
<td>1.16</td>
<td>25.5</td>
<td>22.0</td>
</tr>
<tr>
<td>CI-977</td>
<td>0.0069</td>
<td>&gt; 1.0</td>
<td>&gt; 145</td>
</tr>
<tr>
<td>ICI-199441</td>
<td>0.0071</td>
<td>0.3</td>
<td>42.3</td>
</tr>
<tr>
<td>PD-117302</td>
<td>1.22</td>
<td>33.0</td>
<td>27.0</td>
</tr>
<tr>
<td>Morphine</td>
<td>0.58</td>
<td>6.01</td>
<td>10.4</td>
</tr>
</tbody>
</table>

Table 5. ED₅₀ values (mg/kg, s.c. or p.o.) for antinociceptive effects induced by some opioid agonists in the acetic acid-induced writhing test in mice.
administrations of TRK-820 (0.1-0.8 mg/kg, s.c.), U-50,488H (10-80 mg/kg, s.c.), ICI-199,441 (0.025-0.2 mg/kg, s.c.), or morphine (1.25-10 mg/kg, s.c.) over three days, the development of tolerance to the antinociception induced by each compound at a fixed dose was assessed and tolerance ED$_{50}$ was calculated. Comparing the ratio of tolerance ED$_{50}$ to acute antinociceptive ED$_{50}$ of each compound, TRK-820 was found to develop the least tolerance to antinociception (Table 6) (Suzuki et al., 2004).

An analgesic effect of TRK-820 (i.m.) was also examined using rats with arthritis induced by adjuvant. TRK-820 dose-dependently produced potent and equivalent antinociceptive activity in both arthritic and normal rats in the paw pressure test. Similar results were obtained when morphine was injected i.m. However, the analgesic effect of a conventional κ agonist, ICI-199,441, in the arthritic rats was less potent than in normal rats (Table 7) (Endoh et al., 2000).

<table>
<thead>
<tr>
<th>Compound</th>
<th>Tolerance ED$_{50}$</th>
<th>Acute antinociceptive ED$_{50}$</th>
<th>Ratio of tolerance ED$<em>{50}$/acute antinociceptive ED$</em>{50}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRK-820</td>
<td>0.54</td>
<td>0.0033</td>
<td>163.6</td>
</tr>
<tr>
<td>U-50,488H</td>
<td>30.7</td>
<td>1.16</td>
<td>26.5</td>
</tr>
<tr>
<td>ICI-199,441</td>
<td>0.078</td>
<td>0.0071</td>
<td>11.0</td>
</tr>
<tr>
<td>Morphine</td>
<td>5.72</td>
<td>0.58</td>
<td>9.9</td>
</tr>
</tbody>
</table>

Table 6. ED$_{50}$ values (mg/kg, s.c.) for tolerance and antinociceptive effects induced by some opioid agonists in the acetic acid-induced writhing test.

<table>
<thead>
<tr>
<th>Compound</th>
<th>Normal rat</th>
<th>Arthritic rat</th>
<th>ED50 ratio of arthritic rat/ normal rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRK-820</td>
<td>0.055</td>
<td>0.095</td>
<td>1.7</td>
</tr>
<tr>
<td>ICI-199,441</td>
<td>0.047</td>
<td>0.24</td>
<td>5.1</td>
</tr>
<tr>
<td>Morphine</td>
<td>1.1</td>
<td>1.1</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Table 7. ED$_{50}$ values (mg/kg, i.m.) for antinociceptive effects induced by some opioid agonists in the paw pressure test in normal and arthritic rats.

In streptozotocin-induced diabetic mice, the antinociceptive effects induced by several κ agonists, including TRK-820, were compared in the tail flick test. Intrathecal (i.t.) and i.c.v. administration of TRK-820 produced dose-dependent antinociceptive effects in both diabetic and non-diabetic mice. However, antinociception induced by TRK-820 administered i.t. or i.c.v. in diabetic mice were less potent than antinociception in non-diabetic mice. However, the antinociceptive effects of CI-977 administered i.t., but not i.c.v., in diabetic mice were less potent than those in non-diabetic mice. On the other hand, the antinociceptive effects of ICI-199,441 and R-84760 injected i.c.v., but not i.t., in diabetic mice were less potent than those in non-diabetic mice. These results indicate that the antinociceptive effects of κ agonists in diabetic mice are altered in a region-specific manner in the central nervous system and by chemotypes of κ agonists (Ohsawa et al., 2005).
In acute herpetic and postherpetic pain models induced by herpes simplex virus type-1 infection in mice, TRK-820 dose-dependently and remarkably inhibited the allodynia and hyperalgesia stimulated by von Frey filaments (Takasaki et al., 2004, 2006). The effects of TRK-820, but not morphine, were not significantly different between herpetic and postherpetic pain (Takasaki et al., 2006). TRK-820 (0.1 mg/kg, s.c.) almost completely relieved both allodynia and hyperalgesia in herpetic pain, whereas a high dose of morphine (20 mg/kg, s.c.) did not produce complete inhibition. However, TRK-820 (0.01-0.1 mg/kg, s.c.) did not affect the spontaneous locomotor activity of normal mice (Takasaki et al., 2004). Moreover, repeated administration of TRK-820 (0.1 mg/kg, p.o., twice daily) produced constant inhibition of allodynia and hyperalgesia in herpetic pain. The effects of the fourth administration with TRK-820 were not significantly different from those of the first administration. On the other hand, the effects of morphine rapidly decreased after repeated administration (20 mg/kg, p.o., twice daily). The effects of the third and fourth administration of morphine were significantly weaker than those of the first administration. Pre-treatment with morphine (20 mg/kg, p.o., three times) did not affect the antinociceptive effect of TRK-820 (0.1 mg/kg, p.o.), whereas the effect of morphine (20 mg/kg, p.o.) was significantly reduced (Takasaki et al., 2006). These results indicate that TRK-820 is effective on both herpetic and postherpetic pain in mice. In addition, the analgesic dose of TRK-820 did not develop acute tolerance and induced cross-tolerance to morphine in herpetic pain.

4. Antipruritic effects

4.1 Preclinical studies

The p.o. administration of TRK-820 dose-dependently inhibited scratching behavior induced by histamine in mice, which is one of the representative pruritogenic substances, without obvious suppression of spontaneous locomotor activity. The antiscratching activity of TRK-820 with ED$_{50}$ 7.3 µg/kg was antagonized by nor-BNI (Togashi et al., 2002). TRK-820 was effective in scratching induced by the other pruritogenic substances: substance P (Togashi et al., 2002; Umeuchi et al., 2003; Utsumi et al., 2004), chloroquine (Inan & Cowan, 2004), compound 48/80 (Wang, Y et al., 2005), agmatin (Inan & Cowan, 2006a), and 5’-GNTI (Inan et al., 2009a, 2011) (Table 8). 5’-GNTI-induced scratching was suppressed by both pre-treatment and post-treatment with TRK-820. Tolerance did not develop to the antiscratching effect of TRK-820 in the subchronic study (Inan et al., 2009a).

<table>
<thead>
<tr>
<th>Pruritogenic substance</th>
<th>Antipruritic effect</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histamine</td>
<td>ED$_{50}$ = 7.3 µg/kg, p.o.</td>
<td>Togashi et al., 2002</td>
</tr>
<tr>
<td>Substance P</td>
<td>ED$_{50}$ = 19.6 µg/kg, p.o.</td>
<td>Togashi et al., 2002</td>
</tr>
<tr>
<td>Chloroquine</td>
<td>TRK-820 (120 µg/kg, p.o.) suppressed the scratching almost completely</td>
<td>Inan &amp; Cowan, 2004</td>
</tr>
<tr>
<td>Compound 48/80</td>
<td>ED$_{50}$ = 6.64 µg/kg, s.c.</td>
<td>Wang, Y et al., 2005</td>
</tr>
<tr>
<td>Agmatin</td>
<td>TRK-820 (0.02 mg/kg, s.c.) was effective</td>
<td>Inan &amp; Cowan, 2006a</td>
</tr>
<tr>
<td>5’-GNTI</td>
<td>TRK-820 (20 µg/kg, s.c.) suppressed the scratching almost completely</td>
<td>Inan et al., 2009a</td>
</tr>
</tbody>
</table>

Table 8. The antipruritic effects of TRK-820 against itching behaviors induced by various pruritogenic substances.
Although epidural or i.t. administration of a μ agonist like morphine is an important method for pain management, an itching sensation is the most common side effect (Ballantyne et al., 1988; Cousins & Mather, 1984). The effect of TRK-820 on morphine-induced scratching in mice or primates was also evaluated (Ko & Husbands, 2009; Utsumi et al., 2004; Wakasa et al., 2004). Intramuscular administration of TRK-820 (0.3–1 μg/kg) dose-dependently attenuated scratching induced by morphine (i.t.) in rhesus monkeys without affecting antinociception by morphine (Fig. 3) (Ko & Husbands, 2009).

TRK-820 reportedly exhibited antipruritic effects on spontaneous scratching behavior in aged MRL/lpr mice (a possible model for pruritus in autoimmune disease) (Umeuchi et al., 2008).
2005) or NC/Nag mice maintained in a conventional environment (an animal model for atopic dermatitis) (Nakao et al., 2008), and scratching behavior secondary to cholestasis induced chronic ethynylestradiol injections in rats (Inan & Cowan, 2006b). Interestingly, TRK-820 was effective in scratching behaviors observed in conventional NC/Nag mice, which were considered a model of atopic dermatitis (Fig. 4).

4.2 Clinical studies

Wikström et al. (2005) and Kumagai et al. (2010) reported the results of randomized, double-blind, placebo-controlled clinical studies in which TRK-820 was administered to patients undergoing hemodialysis intravenously or orally (Fig. 5). In these studies, TRK-820 exhibited significant antipruritic effects without severe adverse drug reactions. These outcomes suggest that TRK-820 can be considered a safe agent.

TRK-820 is prescribed in Japan as an antipruritic for hemodialysis. Very recently, Kumagai et al. reported that TRK-820 has been prescribed for approximately 18,000 hemodialysis patients and effective in 70 to 80% (Kumagai et al., 2011).

![Fig. 5. Changes in VAS (visual analogue scale) values from the pre-observation period. All symbols show the mean values of VAS changes. *p < 0.025 compared to placebo, one-sided ANCOVA. Reprinted from Nagase & Fujii, 2011 with permission from Springer Science+Business Media. The VAS test consisted of a 100-mm horizontal line without scale markings. The patients were asked to mark the intensity of itching on the scale, with the right end of the line (100 mm) indicating the strongest possible itching and the left end (0 mm) indicating no itching.](www.intechopen.com)

5. Effects of TRK-820 on drug dependence

5.1 Effects of TRK-820 in the conditioned place preference (CPP) test

The $\mu$ agonists have a rewarding effect, which accounts for the abuse of morphine by humans. In animal models, the rewarding effects of $\mu$ agonists have been evaluated by the conditioned place preference (CPP) and self-administration paradigms (Di Chiara & North, 1992). In contrast to $\mu$ agonists, conventional $\kappa$ agonists such as U-50,488H and U-69,593 generally lack
a rewarding effect (Dykstra et al., 1997). However in the CPP test, animals avoid an environment associated with the administration of the κ agonists, indicating that these drugs have aversive effects (Barr et al., 1994; Funada et al., 1993). In contrast to conventional κ agonists, such as U-50,488H, TRK-820 (3.0-30 μg/kg, s.c.) did not induce significant place aversion in mice at doses producing significant antinociception (Fig. 6) (Nagase, 2010). Notably, TRK-820 exhibited neither preferential nor aversive properties. Recently, the peroral administration of TRK-820 (5.0 μg/day) was reported to show no signs of psychological or physical dependence in an open-labeled clinical trial for one year (Nagase & Fujii, 2011).

Fig. 6. The effect of TRK-820 in the CPP test. Reprinted with permission from Nagase, 2010.

5.2 The effects of TRK-820 on morphine and cocaine-induced rewarding effects

The mechanism of μ agonist-induced rewarding effects is outlined below. The activation of the μ receptor on γ-aminobutyric acid-containing interneurons is likely to disinhibit ventrotegmental area dopaminergic neurons, thereby increasing dopamine release in their terminal areas, including the nucleus accumbens (N.Acc). On the other hand, the activation of the κ receptor decreases dopamine release in the N.Acc (Di Chiara & Imperato, 1988; Spanagel et al., 1992). Therefore, κ agonists may be useful for treating morphine dependence. Indeed, the pretreatment with U-50,488H attenuated the morphine-induced place preference in mice (Funada et al., 1993). TRK-820 also significantly suppressed the place preference produced by morphine, and the effect of TRK-820 was antagonized by pre-treatment with nor-BNI (3.0 mg/kg, s.c.) in mice (Tsuji et al., 2001). In addition, TRK-820 was effective in reducing the rewarding effect produced by cocaine. TRK-820 (20 and 40 μg/kg, i.p.), at doses producing no aversive or sedative effects, suppressed the rewarding effect of cocaine (4.0 mg/kg, i.p.) in rats (Mori et al., 2002). U-50,488H and U-69,593 exhibited similar effects as TRK-820 (Shippenberg et al., 1996; Suzuki et al., 1992). Drug discrimination procedures provide relevant information about neuropharmacological mechanisms underlying the subjective effects of abused drugs, including cocaine, methamphetamine, and opioids, in animals. Therefore, the procedures are potentially useful for identifying candidate therapeutics for the management of drug abuse (Schuster & Johanson, 1988). Pre-treatment with TRK-820 (10 and 20 μg/kg, s.c.) significantly
shifted the dose-response curve for cocaine (10 mg/kg, i.p.) to the right without changing the response rate. This attenuating effect of TRK-820 was completely reversed by pre-treatment with nor-BNI (10 mg/kg, s.c.) (Mori et al., 2002).

5.3 Effects of TRK-820 on the morphine withdrawal response

In humans, withdrawal from the chronic administration of opioids such as morphine results in characteristic behaviors, including anxiety, nausea, insomnia, hot and cold flashes, muscle aches, perspiration, and diarrhea. Such symptoms would pose clinical problems in patients receiving long-term treatment with opioids for pain relief. Rodents that are physically dependent on morphine elicit characteristic signs (jumping, wet dog shakes, rearing, diarrhea, ptosis, and forepaw tremor) when administrated naloxone. The withdrawal signs precipitated by naloxone are used as an index of the physical dependence on morphine. The effects of κ agonists TRK-820 and U-50,488H on the development of physical dependence on morphine were reported. Co-injection of TRK-820 (0.003-0.03 mg/kg, s.c.) during chronic morphine treatment dose-dependently suppressed naloxone-precipitated body weight loss, and the other withdrawal signs in morphine-dependent mice treated with TRK-820 (0.03 mg/kg, s.c.) were significantly fewer than those in untreated mice. In contrast to TRK-820, co-injection of U-50,488H (1.0-10 mg/kg, s.c.) did not inhibit naloxone-precipitated body weight loss and other withdrawal signs (Tsuji et al., 2000).

5.4 The effect of TRK-820 on the nicotine-withdrawal response

Nicotine withdrawal produces characteristic syndromes, including irritability, anxiety, depression, and craving for nicotine. Pre-treatment with TRK-820 (10 and 30 μg/kg, s.c.) or U-50,488H (0.01-1.0 mg/kg, s.c.) has been reported to decrease dose-dependently mecamylamine-precipitated nicotine-withdrawal aversion in nicotine-dependent rats (Ise et al., 2002).

6. Comparison of pharmacological properties between TRK-820 and conventional κ agonists

We described in the previous sections some pharmacological properties of TRK-820 that are different from conventional κ agonists, arylacetamides such as U-50,488H and U-69,593: binding properties (section 2) and exhibition of no preferential and no aversive effect in the CPP paradigm (section 5). As described below, drug discrimination procedures indicate conclusive difference between TRK-820 and arylacetamides.

6.1 Discriminative tests

Drug discrimination procedures have shown that the properties of TRK-820 differ from those of conventional κ agonists, such as U-50,488H. In the cross-substitution tests using rats, U-50,488H (1.0-3.0 mg/kg) substituted for the discriminative stimulus effects of TRK-820 (40 μg/kg, i.p.), whereas TRK-820 (10-76 μg/kg) did not completely substitute for those of U-50,488H (3.0 mg/kg, i.p.). E-2078 (0.3-3.0 mg/kg), but not R-84760 (0.01-0.3 mg/kg), substituted for the discriminative stimulus effects of both TRK-820 and U-50,488H. KT-90 (0.03-3.0 mg/kg), CI-977 (1-30 mg/kg), or ICI-199441 (3.0-56 mg/kg) substituted for the discriminative stimulus effects of U-50,488H, but not for those of TRK-820 (Mori et al., 2004).
In this study, cross-substitution between the discriminative effects of U-50,488H and TRK-820 was not observed. The \( \kappa \) agonists tested in this study, except E-2078, tended to substitute for the discriminative stimulus effects of U-50,488H rather than those of TRK-820. These results suggest that U-50,488H and TRK-820 have differential properties. Furthermore, non-competitive NMDA antagonists phencyclidine (PCP, 0.5-2.0 mg/kg) and MK-801 (10-80 \( \mu \)g/kg) dose-dependently generalized to the discriminative stimulus effects of U-50,488H (3.0 mg/kg, i.p.) in the cross-substitution tests. On the other hand, PCP and MK-801 at doses that generalized to the discriminative stimulus effects of U-50,488H did not generalize to those of TRK-820 (40 \( \mu \)g/kg, i.p.) (Mori et al., 2006). The outcomes clearly indicate different properties between TRK-820 and U-50,488H.

7. Other pharmacological effects

7.1 The effect of TRK-820 on a rat model of schizophrenia

The effects of TRK-820 on hyperlocomotion and stereotyped behaviors (head-weaving, sniffing, and turning) induced by PCP were evaluated. These behaviors are thought to resemble the schizophrenia-like effects in humans. TRK-820 (10–100 \( \mu \)g/kg, s.c.) dose-dependently inhibited PCP (10 mg/kg, i.p.)-induced hyperlocomotion, and this effect was antagonized with nor-BNI (20 mg/kg, s.c.). PCP-induced stereotyped behaviors were also inhibited by treatment with TRK-820 in a dose-dependent manner. These findings that TRK-820 potentially ameliorates abnormal behaviors induced by PCP suggest its therapeutic potential against the symptoms of schizophrenia (Yoshikawa et al., 2009).

7.2 The effect of TRK-820 on dyskinesia symptoms in a parkinsonian rat model

The effects of TRK-820 on rotational behavior were investigated in unilateral 6-hydroxydopamine (6-OHDA)-treated rats (hemi-parkinsonian rats), and on dyskinesia produced by administering L-DOPA to hemi-parkinsonian rats for 3 weeks (dyskinesia rats). TRK-820 significantly ameliorated abnormal behavior in hemi-parkinsonian rats at 30 \( \mu \)g/kg (s.c.), and L-DOPA induced dyskinesia at 10 and 30 \( \mu \)g/kg (s.c.). This effect was antagonized by pretreatment with nor-BNI (20 mg/kg, s.c.). Additionally, co-administration of TRK-820 (3 and 10 \( \mu \)g/kg, s.c.) with L-DOPA for 3 weeks suppressed the development of L-DOPA-induced dyskinesia. TRK-820 may be a suitable drug for the treatment of parkinsonian patients with dyskinesia symptoms (Ikeda et al., 2009).

7.3 The diuretic effect of TRK-820 in rats

Diuresis is a well-recognized effect of conventional \( \kappa \) agonists in animals and humans. A diuretic effect of TRK-820 in rats has also been reported. TRK-820 (0.005-0.02 mg/kg, s.c.) dose-dependently induced a diuretic effect without developing tolerance, and this effect was inhibited by selective \( \kappa \) antagonist 5'-GNTI (Inan et al., 2009b).

7.4 The effects of TRK-820 on endothelial cell differentiation and development of vasculature

The roles of the opioid \( \kappa \) system in vascular development were investigated (Yamamizu et al., 2011). U-50,488H and TRK-820 significantly inhibited endothelial cell differentiation and vascular formation through the inhibition of cAMP/PKA signaling.
8. Conclusion

TRK-820 was a selective κ agonist. However, its pharmacological properties were different from those of conventional arylacetamide κ agonists, including U-50,488H. A notable feature of TRK-820 was that it showed no preferential or aversive properties, whereas U-50,488H produced aversion. This disparity of properties between TRK-820 and arylacetamide κ agonists was reported to stem from the difference in κ receptor subtypes each compound interacted with: arylacetamide κ agonists would interact with κ₁ receptor subtype, whereas TRK-820 may interact with another κ receptor subtype (perhaps κ₃) (Endoh et al., 1999; 2000; 2001; Tsuji et al., 2000a; 2000b). Although opioid receptors have been classified historically into three types (μ, δ, and κ types) and further divided into several subtypes from the pharmacological viewpoint (Dhawan et al., 1996), only the three major types have been cloned (Satoh & Minami, 1995). Much evidence has been compiled indicating that various receptors, including opioid receptors, exist as homo- or heterodimers of the receptors (George et al., 2000, 2002; Gomes et al., 2000, 2004; Devi, 2001; Levac et al., 2002; Wang, D et al., 2005), and receptor dimerization has been invoked to explain the discrepancy between widely varied pharmacologies and the identification of only three opioid receptor types. Therefore, the disparity of properties between TRK-820 and arylacetamide κ agonists may stem from the difference in receptor dimers each compound interacts with. Both TRK-820 and arylacetamide κ agonists are expected to be useful tools for the investigation of receptor dimerization and/or κ receptor subtype. As mentioned in section 2, a binding assay using [³H]TRK-820 and [³H]U-69,593 is thought to be a facile and useful method for achieving that purpose. However, [³H]TRK-820 is not currently available.

In addition to antipruritic and antinociceptive effects, TRK-820 exhibited various pharmacological effects, such as the treatment of the symptoms of schizophrenia or dyskinesia symptoms of parkinsonian patients, or remedy for drug addiction. Moreover, TRK-820 has been already launched in Japan. TRK-820 is expected not only to be developed with the other indication, such as symptoms of schizophrenia or parkinson's disease, but also to be utilized to investigate pharmacology via the κ receptor.

9. References


ELICITED SCRATCHING BEHAVIOR IN MICE, *Neuroscience*, 163, 1, 23-33, ISSN 0306-4522.


Morphinan Hydrochloride (TRK-820) in Mice, J. Pharmacol. Exp. Ther., 309, 1, 36-41, ISSN 0022-3565.


The history of pharmacology travels together to history of scientific method and the latest frontiers of pharmacology open a new world in the search of drugs. New technologies and continuing progress in the field of pharmacology has also changed radically the way of designing a new drug. In fact, modern drug discovery is based on deep knowledge of the disease and of both cellular and molecular mechanisms involved in its development. The purpose of this book was to give a new idea from the beginning of the pharmacology, starting from pharmacodynamic and reaching the new field of pharmacogenetic and ethnopharmacology.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
